[ad_1]
UPDATE ENDED: 12.24
The experimental COVID-19 vaccine, which is being developed by the University of Oxford, elicits a similar immune response in both the elderly and the young and has fewer side effects among the elderly, British pharmaceutical company AstraZeneca Plc announced today.
An effective COVID-19 vaccine is seen as an important game-changing factor in the fight against the new coronavirus, which has killed more than 1.5 million people, hit the global economy and disrupted the normal lives of people. people from all over the world.
“It is encouraging to see that immunogenicity responses were similar between older and younger adults and that reactivity was lower in older adults, in whom the severity of COVID-19 is greater,” an AstraZeneca spokeswoman told Reuters.
“These results further reinforce all the evidence for the safety and immunogenicity of AZD1222,” the spokesperson added.
The Financial Times wrote today that the experimental vaccine, which the University of Oxford is developing in collaboration with AstraZeneca Plc, activates protective antibodies and lymphocytes in older age groups, which are among those most at risk of COVID-19. . The newspaper cited two people who are aware of this finding.
Immunogenicity blood tests performed on a subset of older people who participated in the Oxford experimental vaccine trial reflect data published in July that showed the vaccine elicited “strong immune responses” in a group of 18 healthy adults 55 years old. added the newspaper.
Details of this finding are expected to be published soon in a clinical trial, said FT, who did not name the form.
AstraZeneca, which is developing this vaccine with researchers at the University of Oxford, is considered one of the pioneers in the fight to create a vaccine that protects against COVID-19.
British Health Secretary Matt Hancock said today that a COVID-19 vaccine is not yet ready, although he is preparing chamber support for a possible release. The minister added that he expects its launch in the first half of 2021.
When asked by the BBC if some people could do it already this year, Hancock replied: “I don’t rule this out, but it’s not my first expectation.”
“We want to be prepared in case everything goes perfectly, but it is not my first expectation that we do it this year. However, the program is going well, but we have not arrived yet,” he said.
The Sun wrote today that London hospital staff were informed that they were ready to receive the first doses of the vaccine being developed by Oxford and AstraZeneca Plc.
The Sun clarified that the hospital, which did not give a name, was informed to prepare for the vaccine from the “week beginning November 2.”
SOURCE: AMPE
